He C, et al. – Via a comprehensive literature search of Pubmed, Embase, VIP, CNKI and WanFang databases up to 16 June 2018, researchers evaluated the prognostic value of hyperuricemia in patients with the acute coronary syndrome (ACS). For this investigation, they selected all observational studies that investigated the prognostic value of hyperuricemia in ACS patients. A total of 9 studies representing 8,776 patients with ACS met inclusion criteria. After adjustment for the conventional risk factors, ACS patients with hyperuricemia had an increased risk of major adverse cardiovascular events (MACEs), all-cause mortality, and cardiovascular mortality. In ACS patients, hyperuricemia independently predicted MACEs and death. Results of this meta-analysis suggested that determining the uric acid level can improve the risk stratification of adverse outcomes in ACS patients.